| Ytd | -23.16% | |
| 1y | -23.16% |
| Open | 7.21 | Prev Close | 7.30 | Low | 7.21 | High | 7.46 | Mkt Cap | 29.55M |
| Vol | 10.00 | Avg Vol | 18.47K | EPS | -12.34 | P/E | -0.59 | Forward P/E | N/A |
| Beta | 0.96 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 7.05 | 200-d Avg | 8.14 | 1yr Est | 0.00 |
Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both
Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, S
Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform ra
The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) w
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent de
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst conse